Sonnet BioTherapeutics Secures Second Patent for IL-18 Variant

Sonnet BioTherapeutics Holdings ( (SONN) ) just unveiled an announcement.

On March 19, 2025, Sonnet BioTherapeutics announced that the USPTO issued a Notice of Allowance for a second patent in the IL-18 variant protein field, covering the amino acid sequence of its variant human IL-18BPR protein. This patent strengthens Sonnet’s intellectual property position and opens potential licensing opportunities independent of its FHAB platform. The company has developed two novel drug candidates, SON-1411 and SON-1400, which incorporate the IL-18BPR variant to potentially enhance cancer treatment by targeting tumor microenvironments.

More about Sonnet BioTherapeutics Holdings

Sonnet BioTherapeutics Holdings, Inc. is an oncology-focused biotechnology company that develops targeted biologic drugs with single or bifunctional action using its proprietary Fully Human Albumin-Binding (FHAB) platform. This technology is designed to target tumor and lymphatic tissue, enhancing the safety and efficacy of immune-modulating biologic drugs.

YTD Price Performance: -13.12%

Average Trading Volume: 159,561

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $4.26M

For an in-depth examination of SONN stock, go to TipRanks’ Stock Analysis page.